LAGUNA HILLS, Calif.,
Dec. 2, 2021 /PRNewswire/
-- Prelude Corporation (PreludeDx™), a leader in
molecular diagnostics and precision medicine for early-stage breast
cancer, announced today it will be presenting new data on its
ongoing prospective PREDICT study of DCIS patients at the 2021 San
Antonio Breast Cancer Symposium (SABCS), being held on December 7 – 10 at the Henry B. Gonzalez
Convention Center in San Antonio,
Texas. PreludeDx will present scientific data
demonstrating a significant (40%) change in radiation therapy (RT)
treatment recommendations when using the
DCISionRT® test.
SABCS Poster Session #P2-08-12, will be presented December 8 at 5:00 p.m.
CT. The poster is entitled, Interim analysis of the
PREDICT Registry: Changes in treatment recommendation for a
biologic signature predictive of radiation therapy (RT) benefit in
patients with DCIS. The PREDICT study is a prospective,
multi-institutional registry for patients who received DCISionRT
testing as part of their routine care. The study included 969
patients treated at 55 sites throughout the US.
"This second interim analysis further validates the value of
utilizing tumor biology in physicians' adjuvant treatment
recommendations for DCIS patients, compared to basing decisions
purely on clinicopathology," said Pat
Whitworth, MD, FACS, Principal Investigator and Breast
Surgical Oncologist Director, Nashville Breast Center; Managing
Partner TME. "Study results demonstrated DCISionRT changed
treatment recommendations of physicians in every subgroup of
clinicopathologic factors (age, grade, size, RTOG 9804) and was the
most strongly associated factor with RT recommendation compared
with these other factors."
"We are pleased to reveal that the PREDICT study, which is now
the largest prospective clinical utility DCIS study in the world,
consistently demonstrates that the integration of DCISionRT into
clinical decision making has substantial impact on RT
recommendations and more personalized treatment decisions," says
Dan Forche, President and CEO of
PreludeDx. "When routinely implemented in practice, DCISionRT
has the ability to successfully prevent over- or under- treatment
of DCIS patients."
Additional SABCS Poster Presentations Include:
SABCS Poster #OT1-11-01, will be presented December 8, at 5:00 pm
CT. The poster is entitled The PREDICT Registry
Australia: A prospective registry study to evaluate the
clinical utility of the DCISionRT test on treatment decisions in
patients with DCIS following breast conserving surgery.
SABCS Poster #OT1-09-02, will be presented December 8, at 5:00 pm
CT. The poster is entitled The PREDICT Registry:
A prospective registry to evaluate the effect of a predictive
assay on treatment decisions in patients with DCIS following breast
conserving therapy.
The primary objective of the two ongoing PREDICT registry
studies is to create a de-identified database of patients, test
results, treatment decisions and outcomes that can be queried to
determine the utility of the DCISionRT test in the diagnosis and
treatment of DCIS of the breast. The resulting data set will
identify the percent of cases in which treatment recommendations
are changed after the test results become available.
About DCISionRT for Breast DCIS
DCISionRT is the only risk assessment test for patients
with ductal carcinoma in situ (DCIS) that predicts radiation
therapy benefit. Patients with DCIS have cancerous cells lining the
milk ducts of the breast, but they have not spread into surrounding
breast tissue. In the US, over 60,000 women are newly diagnosed
with DCIS each year. DCISionRT, developed by PreludeDx on
technology licensed from the University of
California San Francisco, and built on research that began
with funding from the National Cancer Institute, enables physicians
to better understand the biology of DCIS. DCISionRT combines the
latest innovations in molecular biology with risk-based assessment
scores to assess a woman's individual tumor biology along with
other pathologic risk factors and provide a personalized recurrence
risk. The test provides a Decision Score™ that
identifies a woman's risk as low or elevated. Unlike other risk
assessment tools, the DCISionRT test combines protein expression
from seven biomarkers and four clinicopathologic factors, using a
non-linear algorithm to account for multiple interactions between
individual factors in order to better interpret complex biological
information. DCISionRT's intelligent reporting provides a woman's
recurrence risk after breast conserving surgery alone and with the
addition of radiation therapy. In turn, this new information may
help patients and their physicians to make more informed treatment
decisions.
About PreludeDx
PreludeDx is a leading personalized breast cancer diagnostics
company dedicated to serving breast cancer patients and physicians
worldwide. Founded in 2009 with technology licensed from
University of California San Francisco,
PreludeDx has focused on developing precision breast cancer tools
that will impact a patient's treatment decision. Our mission is to
provide patients and physicians with innovative technologies that
improve patient outcomes and reduce the overall cost burden to the
healthcare system. Before making a treatment decision, Know Your
Risk™. PreludeDx is a Fjord Ventures portfolio
company.
For more information on how PreludeDx is making a difference for
patients, please visit the Company's website:
https://preludedx.com and follow us on Twitter @PreludeDx,
Facebook, Instagram and LinkedIn.
PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo,
Decision Score, The DCIS Test, Know Your Risk and Your Biology,
Your Decision are trademarks of Prelude Corporation or its wholly
owned subsidiaries in the United
States and foreign countries.
Media
Contact
|
Investor
Contact
|
Cory Dunn
|
Andrew
Wade
|
760.705.7464
|
949.600.8925
|
cdunn@preludedx.com
|
awade@preludedx.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dcisionrt-demonstrates-40-percent-change-in-radiation-therapy-treatment-recommendation-for-dcis-patients-301435864.html
SOURCE PreludeDx